Lv1
40 积分 2021-07-01 加入
Parkinson’s Disease
16小时前
已完结
Parkinson’s Disease
16小时前
已关闭
Parkinson's Disease
16小时前
已关闭
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
5个月前
已完结
Preliminary exploration of the association of CXCR6+T lymphocytes in T2D
11个月前
已完结
Long‐term and low‐dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy
1年前
已完结
Comparative analysis of membranous and other nephropathy subtypes and establishment of a diagnostic model
1年前
已完结
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
1年前
已完结
[Research advances on efficacy and mechanism of sodium-glucose co-transporter 2 inhibitors in the treatment of metabolic associated fatty liver disease]
2年前
已完结
Hallmarks of aging: An expanding universe
2年前
已完结
皖公网安备34019202002308
